Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Pau Montesinos,et al.

Conclusions:Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat population.Febrile neutropenia and infections were less frequent in the ivosidenib-and-azacitidine group than in the placebo-and-azacitidine group,whereas neutropenia and bleeding were more frequent in the ivosidenib-and-azacitidine group.(Funded by Agios Pharmaceuticals and Servier Pharmaceuticals;AGILE ClinicalTrials.gov number,NCT03173248.).